Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275805 | 0.86 | MAPT (0.55) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL14914028 | 0.83 | MAPT (0.52) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL14914029 | 0.83 | MAPT (0.52) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL20267954 | 0.83 | MAPT (0.52) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL28957927 | 0.83 | MAPT (0.52) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL26633382 | 0.81 | MAPT (0.57) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL29739552 | 0.81 | MAPT (0.57) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL30695914 | 0.81 | MAPT (0.57) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL26633381 | 0.81 | MAPT (0.57) | MAPTRAB9ACHRNB2CHRNA4POLB | |
| SCHEMBL17662808 | 0.81 | MAPT (0.52) | MAPTRAB9ACHRNB2CHRNA4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250103-A1 | PROCESS FOR PREPARING BTK INHIBITORS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11661424-B2 | Process for preparing BTK inhibitors | GENENTECH, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250103-A1 | PROCESS FOR PREPARING BTK INHIBITORS | BTK, SYK, LYN | MAPT 3903/4885RAB9A 2311/4885CHRNB2 4620/4885 |
| US-11661424-B2 | Process for preparing BTK inhibitors | BTK, SYK, LYN | MAPT 3903/4885RAB9A 2311/4885CHRNB2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.